| scholarly article | Q13442814 |
| P50 | author | Frank Lyko | Q56168094 |
| P2093 | author name string | Michael Lübbert | |
| Günter Raddatz | |||
| Nadja Blagitko-Dorfs | |||
| Maria Rius | |||
| Christian Maercker | |||
| Simin Öz | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines | Q28472733 | ||
| Epigenetics in human disease and prospects for epigenetic therapy | Q29547437 | ||
| Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura | Q33259359 | ||
| 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy | Q34770609 | ||
| Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | Q53547181 | ||
| Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. | Q53652472 | ||
| Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. | Q34772133 | ||
| Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells | Q35851931 | ||
| 5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1. | Q36052193 | ||
| Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase | Q36145017 | ||
| In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia | Q36502385 | ||
| Genomic impact of transient low-dose decitabine treatment on primary AML cells | Q36654140 | ||
| DNA methylation as a therapeutic target in cancer | Q36760984 | ||
| DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells | Q36948603 | ||
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. | Q37372837 | ||
| Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells | Q37676784 | ||
| Therapy with azanucleosides for myelodysplastic syndromes | Q37765469 | ||
| Epigenetic cancer therapy: rationales, targets and drugs | Q37969665 | ||
| The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells | Q39132595 | ||
| 5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair | Q39162136 | ||
| Capillary electrophoretic analysis of genomic DNA methylation levels | Q39698069 | ||
| Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation | Q39896184 | ||
| DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. | Q40054309 | ||
| Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms | Q40498918 | ||
| Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. | Q43548377 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e152 | |
| P577 | publication date | 2014-08-26 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells | |
| P478 | volume | 42 |
| Q37269937 | 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1. |
| Q49711997 | AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo |
| Q29147555 | Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer |
| Q93160125 | Intermediate-term memory in Aplysia involves neurotrophin signaling, transcription, and DNA methylation |
| Q36158234 | Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis |
| Q91062619 | Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection |
| Q92659257 | Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells |
| Q36900856 | Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors |
| Q36972667 | The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells |
| Q64095817 | Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion |
Search more.